A Ronchi1, M Montella1, V Argenzio2, A Lucia2, A De Renzo3, R Alfano4, R Franco1, I Cozzolino1. 1. Division of Pathology, Department of Mental and Physical Health and Preventive Medicine, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy. 2. Division of General and GeriatricSurgery, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy. 3. Division of Haematology, Department of Clinical Medicine and Surgery, Università "Federico II", Naples, Italy. 4. Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy.
Abstract
INTRODUCTION: Peri-implant breast seroma is a late clinical presentation of reconstructive surgery or augmentation mammoplasty with breast implants. Pre-operative cytological evaluation of the peri-implant breast seroma is a common clinical approach, showing mainly an inflammatory reaction or more rarely a breast implant-associated anaplastic large cell lymphoma. Herein, we reported the role of cytology in the evaluation of peri-implant breast seroma and its critical pre-operative implications. METHODS: Eight cases of peri-implant breast seroma from files at Luigi Vanvitelli University were identified between January and December 2017. In all cases, seroma was aspirated; cytospins were performed and stained by Papanicolaou stain; finally, in all cases, a cell block was obtained for immunocytochemical evaluation and, in one case, for FISH to detect ALK1-gene translocation. RESULTS: The median age of patients was 48 years and the mean time between the implant placement and the occurrence of peri-implant breast seroma was 18 months. Microscopic examination showed breast implant-associated anaplastic large cell lymphoma in one case, aspecific inflammatory reaction in six cases and silicon-associated reaction in one case. CONCLUSIONS: Peri-implant breast seroma may be caused by several pathological conditions with different clinical behaviour. A proper cytological approach to peri-implant breast seroma allows a correct differential diagnosis between inflammatory conditions and breast implant-associated anaplastic large cell lymphoma and an appropriate management of the patient.
INTRODUCTION: Peri-implant breast seroma is a late clinical presentation of reconstructive surgery or augmentation mammoplasty with breast implants. Pre-operative cytological evaluation of the peri-implant breast seroma is a common clinical approach, showing mainly an inflammatory reaction or more rarely a breast implant-associated anaplastic large cell lymphoma. Herein, we reported the role of cytology in the evaluation of peri-implant breast seroma and its critical pre-operative implications. METHODS: Eight cases of peri-implant breast seroma from files at Luigi Vanvitelli University were identified between January and December 2017. In all cases, seroma was aspirated; cytospins were performed and stained by Papanicolaou stain; finally, in all cases, a cell block was obtained for immunocytochemical evaluation and, in one case, for FISH to detect ALK1-gene translocation. RESULTS: The median age of patients was 48 years and the mean time between the implant placement and the occurrence of peri-implant breast seroma was 18 months. Microscopic examination showed breast implant-associated anaplastic large cell lymphoma in one case, aspecific inflammatory reaction in six cases and silicon-associated reaction in one case. CONCLUSIONS: Peri-implant breast seroma may be caused by several pathological conditions with different clinical behaviour. A proper cytological approach to peri-implant breast seroma allows a correct differential diagnosis between inflammatory conditions and breast implant-associated anaplastic large cell lymphoma and an appropriate management of the patient.
Keywords:
anaplastic lymphoma kinase; breast implant-associated anaplastic large cell lymphoma; breast lymphoma; breast seroma; fluorescence in situ hybridisation
Authors: Elaine S Jaffe; Binita S Ashar; Mark W Clemens; Andrew L Feldman; Philippe Gaulard; Roberto N Miranda; Aliyah R Sohani; Timothy Stenzel; Sung W Yoon Journal: J Clin Oncol Date: 2020-02-11 Impact factor: 44.544
Authors: Eleni Thodou; Maria Befani; George Triantafyllidis; Theodosia Choreftaki; George Kanellis; Nikolaos Giannakoulas Journal: Case Rep Hematol Date: 2019-12-05